Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Among authors: yerushalmi r. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, Slobodin G, Stern MD, Eshed I, Sanalla T, Marcus R, Shimoni A, Yerushalmi R, Shem Tov N, Danylesko I, Avigdor A. Lidar M, et al. Among authors: yerushalmi r. Ann Rheum Dis. 2024 Nov 27:ard-2024-226437. doi: 10.1136/ard-2024-226437. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39603710 No abstract available.
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.
Goldvaser H, Yerushalmi R, Mutai R, Kuchuk I, Toker M, Paluch-Shimon S, Drumea K, Evron E, Sonnenblick A, Gal-Yam E, Sela GB, Shai A, Merose R, Bareket-Samish A, Soussan-Gutman L, Stemmer SM. Goldvaser H, et al. Among authors: yerushalmi r. Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07549-7. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39560822
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression.
Danylesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Toren A, Shouval R, Itzhaki O, Avigdor A, Shimoni A, Nagler A. Danylesko I, et al. Among authors: yerushalmi r. Curr Res Transl Med. 2024 Sep 15;72(4):103471. doi: 10.1016/j.retram.2024.103471. Online ahead of print. Curr Res Transl Med. 2024. PMID: 39305562
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphoma.
Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A. Benjamini O, et al. Among authors: yerushalmi r. Haematologica. 2024 Nov 1;109(11):3566-3577. doi: 10.3324/haematol.2023.284664. Haematologica. 2024. PMID: 38899351 Free PMC article.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Fehm T, et al. Among authors: yerushalmi r. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. Lancet Oncol. 2024. PMID: 38697155 Free article. Clinical Trial.
225 results